Bhubaneswar: In a significant development for the healthcare sector, Chairman 5T and Nabin Odisha VK Pandian, recently undertook a visit to the Sapigen Biologix Vaccine plant located at Odisha Biotech Park, Andharua, Bhubaneswar.
The Sapigen Biologix Vaccine plant, currently in its final phase of commissioning, boasts an impressive production capacity of 2.4 crore doses of various vaccines per day. Once fully operational, this facility will stand as the largest vaccine-producing plant in the country, contributing substantially to India’s vaccine manufacturing capabilities.
During the visit, the chairman meticulously inspected all the sub-units of the plant, engaging with the management and employees. He issued directives to all government agencies, urging their collaboration to expedite the commissioning process, with the ambitious goal of bringing the plant into full operation within the next three months.
The ambitious venture, spearheaded by Dr. Krishna Ella of Bharat Biotech fame, involves a substantial investment of Rs 1500 crores. The plant is set to generate 1500 direct employment opportunities, with a significant emphasis on hiring locally from Odisha. The plant is strategically designed to produce a diverse range of vaccines targeting diseases such as cholera, malaria, among others.
One of the distinctive features of the Sapigen Biologix Vaccine plant is its global outlook. The array of vaccines manufactured here will not only cater to domestic demands but will also be supplied to various parts of the world.
Pandian assured comprehensive support from the government, highlighting the recently approved biotechnology policy by Chief Minister Naveen Patnaik’s cabinet. The Chairman expressed confidence that the establishment of this significant anchor manufacturing plant would attract various complementary biotechnology-related companies to the Odisha Biotech Park. This, in turn, is expected to trigger major investments and job creation in the specialized field of biotechnology.